Research & Literature

HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.

Richards A, Herbst U, Manalang J, et al.

The Australian & New Zealand journal of obstetrics & gynaecology 2015; (55(5)):493-7 doi:10.1111/ajo.12363.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, et al.

The Lancet. Oncology 2016; (17(1)):78-89.

Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.

Taube ET, Denkert C, Sehouli J, et al.

Gynecologic oncology 2016; (140(3)):494-502.

Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.

Yamamoto M, Tsujikawa T, Fujita Y, et al.

Cancer science 2016; (107(4)):478-85 doi:10.1111/cas.12890.

The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?

Ataseven B, Harter P, Grimm C, et al.

Gynecologic oncology 2016; (142(2)):243-7.

Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.

Esselen KM, Cronin AM, Bixel K, et al.

JAMA oncology 2016; (2(11)):1427-1433 doi:10.1001/jamaoncol.2016.1842.

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Wright AA, Bohlke K, Armstrong DK, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(28)):3460-73 doi:10.1200/JCO.2016.68.6907.

Endocrine therapy in epithelial ovarian cancer.

Langdon SP, Gourley C, Gabra H, Stanley B

Expert review of anticancer therapy 2017; (17(2)):109-117 doi:10.1080/14737140.2017.1272414.

S100A1 promotes cell proliferation and migration and is associated with lymph node metastasis in ovarian cancer.

Tian T, Li X, Hua Z, et al.

Discovery medicine 2017; (23(127)):235-245.

Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Oaknin A, Guarch R, Barretina P, et al.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018; (20(3)):274-285 doi:10.1007/s12094-017-1719-x.

High grade serous ovarian carcinomas originate in the fallopian tube.

Labidi-Galy SI, Papp E, Hallberg D, et al.

Nature communications 2017; (8(1)):1093 doi:10.1038/s41467-017-00962-1.

Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.

Ratajska M, Koczkowska M, Żuk M, et al.

Oncotarget 2017; (8(60)):101325-101332 doi:10.18632/oncotarget.20722.

Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.

Lee JY, Kim S, Kim YT, et al.

BMC cancer 2018; (18(1)):601 doi:10.1186/s12885-018-4498-z.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore K, Colombo N, Scambia G, et al.

The New England journal of medicine 2018; (379(26)):2495-2505 doi:10.1056/NEJMoa1810858.

Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.

Wu RC, Wang P, Lin SF, et al.

The Journal of pathology 2019; (248(1)):41-50 doi:10.1002/path.5219.

Mucinous Ovarian Carcinoma.

Morice P, Gouy S, Leary A

The New England journal of medicine 2019; (380(13)):1256-1266 doi:10.1056/NEJMra1813254.

The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels

Cengiz A, Koç ZP, Özcan Kara P, Yürekli Y

Molecular imaging and radionuclide therapy 2019; (28(1)):8-14 doi:10.4274/mirt.galenos.2018.00710.

Expression of miR-26b in ovarian carcinoma tissues and its correlation with clinicopathology.

Lu J, Zhang W, Ding Y, et al.

Oncology letters 2019; (17(5)):4417-4422 doi:10.3892/ol.2019.10117.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, et al.

The Lancet. Oncology 2019; (20(5)):636-648 doi:10.1016/S1470-2045(19)30029-4.

Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.

Deng H, Chen M, Guo X, et al.

Molecular genetics & genomic medicine 2019; (7(6)):e672 doi:10.1002/mgg3.672.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

González-Martín A, Pothuri B, Vergote I, et al.

The New England journal of medicine 2019; (381(25)):2391-2402 doi:10.1056/NEJMoa1910962.

Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.

Haunschild CE, Tewari KS

Future oncology (London, England) 2020; (16(7)):225-246 doi:10.2217/fon-2019-0042.

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Ray-Coquard I, Pautier P, Pignata S, et al.

The New England journal of medicine 2019; (381(25)):2416-2428 doi:10.1056/NEJMoa1911361.

Low-grade Serous Tumors: Are We Making Progress?

Pauly N, Ehmann S, Ricciardi E, et al.

Current oncology reports 2020; (22(1)):8 doi:10.1007/s11912-020-0872-5.

Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis.

Manu V, Hein TA, Boruah D, Srinivas V

Medical journal, Armed Forces India 2020; (76(1)):30-36 doi:10.1016/j.mjafi.2018.06.014.

Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival.

Dabi Y, Huchon C, Ouldamer L, et al.

Journal of translational medicine 2020; (18(1)):134 doi:10.1186/s12967-020-02295-y.

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.

Lyons YA, Reyes HD, McDonald ME, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(6)):845-852 doi:10.1136/ijgc-2019-001124.

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Martins FC, Couturier DL, Paterson A, et al.

British journal of cancer 2020; (123(5)):793-802 doi:10.1038/s41416-020-0900-0.

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Monk BJ, Grisham RN, Banerjee S, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(32)):3753-3762 doi:10.1200/JCO.20.01164.

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials.

Wang Y, Ren F, Song Z, et al.

Frontiers in oncology 2020; (10()):1204 doi:10.3389/fonc.2020.01204.

The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia.

Moharrag A, Yonbawi F, Bashawieh HH, et al.

Cureus 2020; (12(8)):e9518 doi:10.7759/cureus.9518.

Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.

Eakin CM, Norton TJ, Monk BJ, Chase DM

Gynecologic oncology 2020; (159(2)):581-587 doi:10.1016/j.ygyno.2020.08.016.

The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.

Haunschild CE, Tewari KS

Gynecologic oncology 2021; (160(1)):333-345 doi:10.1016/j.ygyno.2020.09.043.

Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.

Hao J, Liu Y, Zhang T, et al.

Critical reviews in oncology/hematology 2021; (157()):103145 doi:10.1016/j.critrevonc.2020.103145.

Systematic Lymph Node Dissection May Be Abolished in Patients With Apparent Early-Stage Low-Grade Mucinous and Endometrioid Epithelial Ovarian Cancer.

Chen J, Yin J, Li Y, et al.

Frontiers in oncology 2021; (11()):705720 doi:10.3389/fonc.2021.705720.

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.

Berek JS, Renz M, Kehoe S, et al.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2021; (155 Suppl 1()):61-85 doi:10.1002/ijgo.13878.

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

Banerjee S, Moore KN, Colombo N, et al.

The Lancet. Oncology 2021; (22(12)):1721-1731 doi:10.1016/S1470-2045(21)00531-3.

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.

Harter P, Sehouli J, Vergote I, et al.

The New England journal of medicine 2021; (385(23)):2123-2131 doi:10.1056/NEJMoa2103294.

Low-Grade Serous Carcinoma of the Ovary: The Current Status.

Babaier A, Mal H, Alselwi W, Ghatage P

Diagnostics (Basel, Switzerland) 2022; (12(2)) doi:10.3390/diagnostics12020458.

Smartphone-based Ecological Momentary Assessment to study "scanxiety" among Adolescent and Young Adult survivors of childhood cancer: A feasibility study.

Heathcote LC, Cunningham SJ, Webster SN, et al.

Psycho-oncology 2022; (31(8)):1322-1330 doi:10.1002/pon.5935.

The roles and limitations of bevacizumab in the treatment of ovarian cancer.

Nakai H, Matsumura N

International journal of clinical oncology 2022; (27(7)):1120-1126 doi:10.1007/s10147-022-02169-x.

The utility of physical examination in ovarian cancer recurrence detection: a retrospective analysis informing virtual surveillance care.

Janke MJ, Santiago S, Straubhar AM, Uppal S

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(7)):913-917 doi:10.1136/ijgc-2022-003506.

Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.

Hlaváč V, Holý P, Václavíková R, et al.

Life science alliance 2022; (5(12)) doi:10.26508/lsa.202201551.

Evaluation of external validity of the OVHIPEC-1 trial in a real-world population.

van Stein RM, Sikorska K, van der Aa MA, et al.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2023; (161(2)):640-648 doi:10.1002/ijgo.14618.

PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.

Chelariu-Raicu A, Trillsch F, Burges A, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(5)):812-822 doi:10.1136/ijgc-2022-003990.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Ray-Coquard I, Leary A, Pignata S, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2023; (34(8)):681-692 doi:10.1016/j.annonc.2023.05.005.

Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.

Craig O, Nigam A, Dall GV, Gorringe K

Cold Spring Harbor perspectives in medicine 2023; (13(9)) doi:10.1101/cshperspect.a038190.

Seeing beyond the tumor: computed tomography image-based radiomic analysis helps identify ovarian clear cell carcinoma subtype in epithelial ovarian cancer.

Ren J, Mao L, Zhao J, et al.

La Radiologia medica 2023; (128(8)):900-911 doi:10.1007/s11547-023-01666-x.

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.

Li N, Zhu J, Yin R, et al.

JAMA oncology 2023; (9(9)):1230-1237 doi:10.1001/jamaoncol.2023.2283.

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria.

Shittu KA, Rabiu KA, Akinola OI, et al.

Ecancermedicalscience 2023; (17()):1568 doi:10.3332/ecancer.2023.1568.

An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective.

Cordani N, Bianchi T, Ammoni LC, et al.

International journal of molecular sciences 2023; (24(15)) doi:10.3390/ijms241511890.

Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer.

Luo Y, Pan R, Rao H, et al.

International journal of general medicine 2024; (17()):75-84 doi:10.2147/IJGM.S445660.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002).

Yamamoto S, Tsuchiya M, Iihara H, et al.

Journal of Cancer 2024; (15(6)):1487-1497 doi:10.7150/jca.91675.

Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.

Murawski M, Jagodziński A, Bielawska-Pohl A, Klimczak A

Cells 2024; (13(4)) doi:10.3390/cells13040345.

Endometriosis-Related Ovarian Cancer: Where Are We Now? A Narrative Review towards a Pragmatic Approach.

Centini G, Schettini G, Pieri E, et al.

Journal of clinical medicine 2024; (13(7)) doi:10.3390/jcm13071933.

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Monk BJ, Barretina-Ginesta MP, Pothuri B, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2024; (35(11)):981-992 doi:10.1016/j.annonc.2024.08.2241.

Two possible entities of endometriosis-associated ovarian cancer: correlated or incidental?

Mezzapesa F, Dondi G, Coada CA, et al.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025; (35(4)):101634 doi:10.1016/j.ijgc.2025.101634.

The prognosis impact of NACT-IDS and PDS in advanced ovarian cancer: a systematic review and meta-analysis.

Xie Q, Cui M

Journal of gynecologic oncology 2025; (36(4)):e61 doi:10.3802/jgo.2025.36.e61.

The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review.

Momenimovahed Z, Mazidimoradi A, Allahqoli L, Salehiniya H

Cancer reports (Hoboken, N.J.) 2025; (8(3)):e70142 doi:10.1002/cnr2.70142.

Management of early-stage ovarian cancer: Open questions and debated issues.

Salutari V, Giudice E, Rapisarda E, et al.

Critical reviews in oncology/hematology 2025; (210()):104704 doi:10.1016/j.critrevonc.2025.104704.

Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta-Analysis.

Zou Z, Xia L, Tang S, et al.

Cancer innovation 2025; (4(4)):e70015 doi:10.1002/cai2.70015.

Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies.

Zhang M, Zhu J, Bao Y, et al.

Frontiers in bioengineering and biotechnology 2025; (13()):1589841 doi:10.3389/fbioe.2025.1589841.

Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

Blanc-Durand F, Ngoi N, Lim D, et al.

Cancer treatment reviews 2025; (138()):102977 doi:10.1016/j.ctrv.2025.102977.

Treatment of ovarian cancer: From the past to the new era (Review).

Alrosan K, Alrosan AZ, Heilat GB, et al.

Oncology letters 2025; (30(2)):384 doi:10.3892/ol.2025.15130.

Treatment, outcomes, and resource utilization among patients with metastatic breast and advanced epithelial ovarian cancer, by BRCA1/2 and HRD status.

Cruz GI, Kane KL, Matsuno RK, et al.

The oncologist 2025; (30(8)) doi:10.1093/oncolo/oyaf100.

A Narrative Review of Clinical and Molecular Criteria for the Selection of Poor Candidates for Optimal Cytoreduction in Epithelial Ovarian Cancer.

Pariza G, Mavrodin C, Potorac A, et al.

Life (Basel, Switzerland) 2025; (15(8)) doi:10.3390/life15081318.

Comparative Retrospective Analysis of Ovarian Cancer Treatment Outcomes: Neoadjuvant Therapy with and without Surgical Intervention.

Iyengar R, Murali Mohan Reddy G, Kumaresan P

Indian journal of surgical oncology 2025; (16(4)):876-881 doi:10.1007/s13193-024-02144-0.

Tumor Immune Microenvironment and Checkpoint Inhibition in Clear Cell Ovarian Carcinoma: Bridging Tumor Biology and Clinical Application in Immunotherapy.

Borella F, Capella G, Cosma S, et al.

Current issues in molecular biology 2025; (47(9)) doi:10.3390/cimb47090726.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

"You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

Derry-Vick H, Prigerson HG, Hahne J, et al.

Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma.

Kabirian R, Gaillard T, Bello-Roufai D, et al.

Bulletin du cancer 2026; (113(4)):533-540 doi:10.1016/j.bulcan.2025.11.005.

Quality of life in ovarian cancer patients receiving maintenance therapy with bevacizumab versus PARPi: a network meta-analysis.

Wu D, Wang Z, Yang W, et al.

Expert review of anticancer therapy 2026; (26(6)):759-765 doi:10.1080/14737140.2025.2610267.

Impact of Lymph Node Involvement on Prognosis and Survival in Patients With Ovarian Carcinoma: A Clinicopathological Correlation Study.

Naz Z, Pervaiz J, Azmat J, et al.

Cureus 2025; (17(12)):e100115 doi:10.7759/cureus.100115.

Targeting RAS-RAF-MEK-ERK signaling in mucinous ovarian cancer: a translational evidence synthesis and clinical framework.

Bartl T, Cacsire Castillo-Tong D

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; (36(4)):104485 doi:10.1016/j.ijgc.2026.104485.

Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer.

Nishimyo K, Ishikawa KB, Aoki D, et al.

Targeted oncology 2026; (21(2)):255-268 doi:10.1007/s11523-026-01202-7.

Serous endometrial cancer with an elusive preoperative diagnosis.

Rajaram S, Singh L, - B, Nagar S

BMJ case reports 2026; (19(3)) doi:10.1136/bcr-2025-270356.